Related Experiment Video
Updated: Jul 21, 2025
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Promising Highly Targeted Therapies for Cholangiocarcinoma: A Review and Future Perspectives
Masaki Kuwatani1, Naoya Sakamoto1
1Department of Gastroenterology and Hepatology, Hokkaido University Hospital, North 14, West 5, Kita-ku, Sapporo 060-8648, Japan.
Abstract:
To overcome the poor prognosis of cholangiocarcinoma (CCA), highly targeted therapies, such as antibody-drug conjugates (ADCs), photodynamic therapy (PDT) with/without systemic chemotherapy, and experimental photoimmunotherapy (PIT), have been developed. Three preclinical trials have investigated the use of ADCs targeting specific antigens, namely HER2, MUC1, and glypican-1 (GPC1), for CCA. Trastuzumab emtansine demonstrated higher antiproliferative activity in CCA cells expressing higher levels of HER2. Similarly, "staphylococcal enterotoxin A-MUC1 antibody" and "anti-GPC1 antibody-monomethyl auristatin F" conjugates showed anticancer activity. PDT is effective in areas where appropriate photosensitizers and light coexist. Its mechanism involves photosensitizer excitation and subsequent reactive oxygen species production in cancer cells upon irradiation. Hematoporphyrin derivatives, temoporfin, phthalocyanine-4, talaporfin, and chlorine e6 derivatives have mainly been used clinically and preclinically in bile duct cancer. Currently, new forms of photosensitizers with nanotechnology and novel irradiation catheters are being developed. PIT is the most novel anti-cancer therapy developed in 2011 that selectively kills targeted cancer cells using a unique photosensitizer called "IR700" conjugated with an antibody specific for cancer cells. PIT is currently in the early stages of development for identifying appropriate CCA cell targets and irradiation devices. Future human and artificial intelligence collaboration has potential for overcoming challenges related to identifying universal CCA cell targets. This could pave the way for highly targeted therapies for CCA, such as ADC, PDT, and PIT.
Insights
Targeted therapies like antibody-drug conjugates (ADCs), photodynamic therapy (PDT), and photoimmunotherapy (PIT) show promise for cholangiocarcinoma (CCA). Research is ongoing to identify effective targets and delivery methods for these advanced cancer treatments.
Area of Science:
- Oncology
- Biotechnology
- Nanomedicine
Background:
- Cholangiocarcinoma (CCA) has a poor prognosis, necessitating the development of advanced treatment strategies.
- Highly targeted therapies are emerging as promising options for managing CCA.
- Current research focuses on antibody-drug conjugates (ADCs), photodynamic therapy (PDT), and photoimmunotherapy (PIT).
Purpose of the Study:
- To review the preclinical and clinical development of targeted therapies for cholangiocarcinoma.
- To highlight the mechanisms and potential of ADCs, PDT, and PIT in CCA treatment.
- To explore future directions, including AI collaboration, for optimizing CCA therapies.
Main Methods:
- Review of preclinical trials investigating ADCs targeting HER2, MUC1, and GPC1 in CCA.
- Analysis of PDT mechanisms and photosensitizers used in bile duct cancer.
- Examination of the novel approach of photoimmunotherapy (PIT) for targeted cancer cell destruction.
Main Results:
- ADCs like Trastuzumab emtansine showed antiproliferative activity in HER2-expressing CCA cells.
- Various photosensitizers are utilized in PDT for bile duct cancer, with ongoing advancements in nanotechnology.
- Photoimmunotherapy (PIT) is an emerging targeted therapy in early development for CCA.
Conclusions:
- Targeted therapies including ADCs, PDT, and PIT offer significant potential for improving cholangiocarcinoma outcomes.
- Further research is crucial for identifying optimal CCA targets and refining delivery systems for these therapies.
- Future advancements may involve human-AI collaboration to overcome challenges in universal target identification for CCA.
More Related Videos
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...